Dr. Christian Weber or Dr. Emiel van der Vorst, Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Pettenkoferstr. 9, 80336 Munich, Germany, Tel.: +49 89 4400 54610, Fax: + 49 89 4400 54352, E-mail:
Thromb Haemost. 2017 Jun 28;117(7):1258-1264. doi: 10.1160/TH16-10-0814. Epub 2017 Jun 8.
Even two centuries after they were first described, atherosclerosis and atherothrombosis remain among the leading causes of death worldwide. Over the last decades it has become clear that atherosclerosis is not only a lipid-driven disease but also a multifactorial process largely driven by inflammatory mediators, an insight that has instigated additional research and drug development focussing on anti-inflammatory therapies. In this review, we will provide a brief historical overview, followed by a more general synopsis of the range of currently available state-of-the-art therapies for atherosclerosis and atherothrombosis. Finally, we will highlight some of the promising therapeutic strategies that are currently under intense investigation. We believe that the next years will witness highly interesting developments and clinical trials investigating yet more novel therapies, and at the same time looking into potential combinations of all available therapies. This prospect closes in on the ultimate goal, which is to reduce the residual risk that still persists despite present therapeutic options.
即使在首次描述它们两个世纪之后,动脉粥样硬化和动脉血栓形成仍然是全球主要的死亡原因之一。在过去的几十年中,人们已经清楚地认识到,动脉粥样硬化不仅是一种脂质驱动的疾病,而且还是一种主要由炎症介质驱动的多因素过程,这一认识促使人们进行了更多的研究和药物开发,重点关注抗炎治疗。在这篇综述中,我们将提供一个简短的历史概述,然后更全面地概述目前可用于动脉粥样硬化和动脉血栓形成的各种最先进的治疗方法。最后,我们将重点介绍一些目前正在深入研究的有前途的治疗策略。我们相信,未来几年将见证极具意义的发展和临床试验,探索更多新的治疗方法,同时研究所有现有治疗方法的潜在联合应用。这一前景接近最终目标,即降低尽管目前有治疗选择但仍然存在的残余风险。